Pearl Ling Qi Tang Clinical Study Of Treatment Of Chronic Hepatitis B

Hepatitis B virus(HBV) infection is the disease which endangering human health globally.According to a nationwide epidemiological survey,China's population of HBV infection as high as 60%,of which about 120 million are chronic carriers of the virus,accounting for 10 percent of China's population. How to treat chronic hepatitis B is the world's issues of concern to scholars all the world.Chinese medicine has thousands of years to fight with infectious diseases and the history of ancient medicine in theory and clinical practice,made a significant contribution.ZhangChaoXi,the liver disease expert,as associate professor of clinical treatment in the study found that Qi Deficiency and toxin exist is evidence of chronic hepatitis B as abasic type,most often in clinical. Clinical data collection in the Qi Deficiency and toxin exist is also the largest number datas and the most research value.ObjectivePearl Ling Qi Tang observed treatment of chronic hepatitis B patients with Qi-deficiency type of toxin exist-clinical efficacy and safety,in particular, this method of HBV-DNA results.MethodsIn accordance with the principles of randomized,all patients will be divided into treatment group,and control group,with each 60 cases.Treatment group use Pearl Ling Qi Tang,a Chinese medicine every day,twice a day;the control group given entecavir 0.5mg,once a day,3 months for a course,observe the three treatments and six-month follow-up.Clinical efficacy criteriaReference to "Chinese medicine treatment of viral hepatitis clinical researchguiding principles" to determine efficacy of standard-setting[editor-in-chief Zheng Xiaoyu,Chinese medicine guiding principles for clinical research of new drugs(for trial implementation), Beijing:China Medical Science and Technology Press,2002:143-151 effect]criteria:1.basic cure:the disappearance of subjective symptoms; hepatosplenomegaly stable or reduced,without tenderness and knocking pain; normal liver function testing;indicators of the stability of the above more than 1 year.Does not require indicators of hepatitis B virus replication (HBV-DNA,HBsAg,HBeAg) negative.2.Effective:Clinical symptoms of decline in the value of total score≥1/3but＜2/3;stable hepatosplenomegaly,and no significant tenderness and knocking pain;liver function testing and normal or decreased morse than 50%of original value,and who continued in March.3. Invalid:after the end of treatment,clinical symptoms of decline in the value of total score＜1/3,1iver function did not decline.Reference to "Chinese medicine treatment of viral hepatitis clinical research of the Guiding Principles" standards on its own.Above,respectively before and after treatment for 4 weeks,12 weeks, 24 weeks testing,to before and after treatment for 12 weeks for control.The results1 Comparison of clinical efficacy between the two groups1.The two groups after the effects of treatment efficacy index(%)Note:the treatment group and clinical efficacy of the control group with statistical significance comparedTreatment group and control group compared with the clinical efficacy of statistical significance(P＜0.05)2 The treatment group and control group of indicators of the efficacy of HBV markers compared the difference was not significant:p＞0.05;changes before and after treatment the difference was not significant.3 The treatment of symptoms and signs before and after the change,the two groups before and after treatment ALT changes disappear after administration / governance of the former(normalization rate%) have increased.That the treatment group and the control group the changes in both of these projects reflect the trend of improvement in the disease,while the treatment group than the control group.4 The two groups before and after the treatment of symptoms of changes in the control group of patients after treatment of different drugs in the clinical symptoms and signs have improved to varying degrees,but the treatment group prioritly.The treatment group not only play the role of ALT are often complex,and other indicators of liver function such as the has reduced the role.5 The two groups before and after treatment ALT normalization changes in the treatment group rate of 66.7%percent,only 63.3%in control group.6 HBV markers were detected compared to the situation in indicator of changes in:the treatment group the rate of HBV-DNA negative 38.3%,HBeAg negative conversion rate was 23.3%;control group,HBV-DNA negative conversion rate of 51.6%,HBeAg negative conversion rate was 40%,treatment group and control group HBV-DNA showed no significant difference(P＞0.05).7 compare side effects:There were no adverse reactions and side effectsConclusion of the studyPearl Ling Tang Qi Tang can reduce the patientsof chronic hepatitis B with Qi Deficiency and toxin exist symptoms,signs,restoration of liver function,and to some extent,inhibit the replication of hepatitis B virus,and its reliable efficacy,good safety performance,it is worth to promote the use of clinical.